NuCana BioMed, an Edinburgh UK-based biopharmaceutical company focused on anti-cancer therapies, has closed a £6.74m (approximately $10.4m) Series A venture funding.
The round was led by Sofinnova Partners, with participation from Morningside Ventures, Scottish Investment Bank’s Scottish Venture Fund and Alida Capital International.
The company intends to use the funds to take a range of known cancer drugs into clinical development.
Founded in 2008 by CEO Hugh Griffith and Executive Chairman Chris Wood, NuCana BioMed has exclusive worldwide rights to the ProTide technology in cancer, which allows to target specific patients whose cancers are resistant to some of the anti-cancer drugs in common use today.
NuCana’s first compound, a gemcitabine ProTide, will enter clinical studies in early 2012, rapidly followed by two other ProTides.
FinSMEs
29/11/2011